Christie Yao1, Jill B Rich1, Ian F Tannock2, Bostjan Seruga3, Kattleya Tirona4, Lori J Bernstein4. 1. 1Department of Psychology,York University,Toronto,Ontario,Canada. 2. 2Department of Medical Oncology,Princess Margaret Cancer Centre,Toronto,Ontario,Canada. 3. 3Department of Medical Oncology,Institute of Oncology Ljubljana and University of Ljubljana,Ljubljana,Slovenia. 4. 4Department of Supportive Care,Cancer Rehabilitation and Survivorship Program,Princess Margaret Cancer Centre,Toronto, Ontario,Canada.
Abstract
OBJECTIVES: Chemotherapy has adverse effects on cognitive performance in women treated for breast cancer, but less is known about the period before chemotherapy. Studies have focused on mean level of performance, yet there is increasing recognition that variability in performance within an individual is also an important behavioral indicator of cognitive functioning and underlying neural integrity. METHODS: We examined intraindividual variability (IIV) before chemotherapy and surgery in women diagnosed with breast cancer (n=31), and a healthy control group matched on age and education (n=25). IIV was calculated across trials of a computerized Stroop task, including an examination of the slowest and fastest trials of reaction time (RT) responses. RESULTS: The groups were equivalent on overall accuracy and speed, and participants in both groups were less accurate and slower on incongruent trials compared with congruent trials. However, women with breast cancer became more variable with increased task difficulty relative to healthy controls. Among the slowest RT responses, women with breast cancer were significantly more variable than healthy controls on incongruent trials. This suggests that a specific variability-producing process (e.g., attentional lapses) occurs in task conditions that require executive control (e.g., incongruent trials). CONCLUSIONS: Results are consistent with other evidence of executive dysfunction among women treated for breast cancer. These findings highlight the importance of pretreatment assessment and show that variability in performance provides information about cognition that measures of central tendency do not.
OBJECTIVES: Chemotherapy has adverse effects on cognitive performance in women treated for breast cancer, but less is known about the period before chemotherapy. Studies have focused on mean level of performance, yet there is increasing recognition that variability in performance within an individual is also an important behavioral indicator of cognitive functioning and underlying neural integrity. METHODS: We examined intraindividual variability (IIV) before chemotherapy and surgery in women diagnosed with breast cancer (n=31), and a healthy control group matched on age and education (n=25). IIV was calculated across trials of a computerized Stroop task, including an examination of the slowest and fastest trials of reaction time (RT) responses. RESULTS: The groups were equivalent on overall accuracy and speed, and participants in both groups were less accurate and slower on incongruent trials compared with congruent trials. However, women with breast cancer became more variable with increased task difficulty relative to healthy controls. Among the slowest RT responses, women with breast cancer were significantly more variable than healthy controls on incongruent trials. This suggests that a specific variability-producing process (e.g., attentional lapses) occurs in task conditions that require executive control (e.g., incongruent trials). CONCLUSIONS: Results are consistent with other evidence of executive dysfunction among women treated for breast cancer. These findings highlight the importance of pretreatment assessment and show that variability in performance provides information about cognition that measures of central tendency do not.
Authors: Alexandra M Gaynor; Denise Pergolizzi; Yesne Alici; Elizabeth Ryan; Katrazyna McNeal; Tim A Ahles; James C Root Journal: Brain Stimul Date: 2020-04-27 Impact factor: 8.955
Authors: Joseph M Gullett; Ronald A Cohen; Gee Su Yang; Victoria S Menzies; Robert A Fieo; Debra L Kelly; Angela R Starkweather; Colleen K Jackson-Cook; Debra E Lyon Journal: Psychooncology Date: 2019-03-14 Impact factor: 3.894
Authors: Nadia Miladi; Richi Dossa; Maman Joyce Dogba; Marie Immacula Fabienne Cléophat-Jolicoeur; Bruno Gagnon Journal: Support Care Cancer Date: 2019-06-28 Impact factor: 3.603
Authors: Denise Pergolizzi; James C Root; Hong Pan; David Silbersweig; Emily Stern; Steven D Passik; Tim A Ahles Journal: Brain Imaging Behav Date: 2019-12 Impact factor: 3.978
Authors: Zev M Nakamura; Allison M Deal; Donald L Rosenstein; Laura J Quillen; Stephanie A Chien; William A Wood; Thomas C Shea; Eliza M Park Journal: Support Care Cancer Date: 2020-08-23 Impact factor: 3.603